Northwestern University

Cavalon Therapeutics, Inc.

Dalton James Surmeier, Jr

Richard B Silverman

Garry Cooper

Jack Nguyen

Soosung Kang

Soo Sung Kang

Weixing Shen

Steven M Graves

The present disclosure provides extended or sustained release compositions of a dihydropyridine calcium channel blocker, specifically isradipine, and method of using the compositions for the treatment of neurological disorders, wherein the composition provides sustained plasma levels of the dihydropyridine calcium channel blocker.

Dihydropyridine compositions and methods for treating neurological disorders

Provided herein are compositions and methods to reduce toxicity resulting from pharmaceutical treatment, that can lead to increased risk of developing Parkinson's disease (PD) and/or acceleration of PD-associated deterioration.

Compositions and methods to reduce pharmaceutical-induced toxicity

Provided herein are compositions and methods for the treatment and of neurodegenerative disorders and levodopa-induced dyskinesias. In particular, A2a receptor antagonists are provided, as well as methods for the use of A2a receptor antagonists in the treatment of neurodegenerative disorders (e.g., Parkinsons disease) and the treatment and/or prevention levodopa-induced dyskinesias associated with such treatment.

Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias

The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.

Growing community of inventors

Chicago, IL, United States of America

Dalton James Surmeier, Jr